Bosutinib
BOSULIF
NADAC/unit
N/A
No Shortage
Tier 1: 89.7%
PA Req: 496.0%
1 Manufacturers
2 ANDAs
BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), ne....
Generic Manufacturers
ALEMBIC PHARMACEUTICALS LTDPF PRISM CV
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.